clinical trial · NCT06485635
Real-life-persistence to Antifibrotic Treatments
Boehringer Ingelheim·—·completed·n = 10,646
Idiopathic Pulmonary FibrosisNintedanibPirfenidone
brief summary
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment. Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.
started
Oct 16, 2024
primary completion
Apr 7, 2026
completion
Apr 7, 2026
last updated
Apr 15, 2026
official title
Real-life-Persistence to Antifibrotic Treatments
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol